Adriel most recently worked in corporate development at Forty Seven, a next-generation clinical stage immuno-oncology company. There, he spearheaded financing, communications, and commercial development. While a transitional postdoc fellow at Stanford University School of Medicine, he helped secure Forty Seven’s first venture capital investor and develop the company’s lead compound. His research, focused on the immune system and oncology, has led to multiple clinical trials. Adriel is passionate about advancing the latest scientific and clinical research to create treatments for patients.